BGA
TGTX icon

Belmont Global Advisors’s TG Therapeutics TGTX Stock Holding History

Belmont Global Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-40,000
Closed -$664K – 77
2015
Q2 		$664K Buy
+40,000
New +$633K 0.74% 28

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Belmont Global Advisors's TGTX Position: Q3 2015 in Review

Belmont Global Advisors sold out of TG Therapeutics (TGTX) in Q3 2015, closing a stake of 40,000 shares — an estimated $664K sold.

Belmont Global Advisors first reported a position in TGTX in Q2 2015 and held it in 1 quarter. The position peaked at $664K in Q2 2015. 83 funds tracked by Wall St. Rank hold TGTX as of Q3 2015.

  • Belmont Global Advisors reported no remaining TG Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Belmont Global Advisors sold 40,000 TG Therapeutics shares in Q3 2015, an estimated $664K.
  • Belmont Global Advisors first reported a position in TG Therapeutics in Q2 2015 and held it in 1 quarter.
  • Belmont Global Advisors's TG Therapeutics position peaked at $664K in Q2 2015.
  • 83 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2015.

Based on Belmont Global Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.